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Objective—Persons with schizophrenia die earlier than the general population, in large part due to
cardiovascular disease. The study objective was to examine effects of different antipsychotic
treatments on estimates of 10 year coronary heart disease (CHD) risk calculated by the Framingham
Heart Study formula.
Method—Change in ten-year risk for CHD was compared between treatment groups in 1125
patients followed for 18 months or until treatment discontinuation in the Clinical Antipsychotic Trials
of Intervention Effectiveness (CATIE) Schizophrenia Trial.
Results—The covariate-adjusted mean change in 10-year CHD risk differed significantly between
treatments. Olanzapine was associated with a 0.5% (SE 0.3) increase and quetiapine, a 0.3% (SE 0.3)
increase; whereas risk decreased in patients treated with perphenazine, −0.5% (SE 0.3), risperidone,
−0.6% (SE 0.3), and ziprasidone −0.6% (SE 0.4). The difference in 10-year CHD risk between
olanzpaine and risperidone was statistically significant (p=0.004). Differences in estimated 10 year
CHD risk between drugs were most marked in the tertile of subjects with a baseline CHD risk of at
least 10%. Among individual CHD risk factors used in the Framingham formula, only total and HDL
cholesterol levels differed between treatments.
Conclusions—These results indicate that the impact on 10-year CHD risk differs significantly
between antipsychotic agents, with olanzapine producing the largest elevation in CHD risk of the
agents studied in CATIE.
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1.0 Introduction
Persons with schizophrenia have increased death rates, with standardized mortality ratios up
to three times those for the general population. (Felker, Yazel et al. 1996; Brown 1997) While
most studies report elevated risks for suicide and accidental death, more recent work suggests
much premature mortality may be due to cardiovascular disease. (Osby, Correia et al. 2000;
Colton and Ronald W. Manderscheid 2006)
People with schizophrenia have a higher prevalence of most traditional factors contributing to
elevated coronary heart disease (CHD) risk. Smoking rates, in particular, are much higher than
the general population. (Goff, Henderson et al. 1992; Lohr and Flynn 1992) Unhealthy diet
and physical inactivity also appear increased and contribute to the high prevalence of obesity.
(Daumit GL, Clark JM et al. 2003; McCreadie 2003; Strassnig, Brar et al. 2003; Daumit,
Goldberg et al. 2005; Brown, Goetz et al. 2006) In large part stemming from obesity, the
increased risk for diabetes mellitus in schizophrenia also is well known. Recent published
baseline data from the CATIE Trial provide evidence that hypertension and low HDL
cholesterol are more prevalent in patients with schizophrenia than the general population.
(Goff, Sullivan et al. 2005; McEvoy, Meyer et al. 2005)
Although elevation in CHD risk factors is due in part to unhealthy lifestyles and lower quality
primary care in people with schizophrenia, atypical antipsychotics likely contribute
substantially to increasing CHD risk factors through effects on weight gain, glucose
dysregulation and lipid abnormalities. (Allison, Mentore et al. 1999; Meyer and Koro 2004;
Kreyenbuhl, Dickerson et al. 2006; Newcomer and Haupt 2006) Extensive use of these agents
has raised important concerns about cardiovascular health for populations using these
medications chronically. (Marder, Essock et al. 2004)
The Framingham risk equation, derived from the Framingham Heart Study and Framingham
Offspring Study cohorts, provides a validated calculation of 10-year risk of CHD, including
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angina, myocardial infarction and cardiac death, tested in a variety of populations.(Wilson,
D'Agostino et al. 1998; D'Agostino 2001) Using baseline assessments of schizophrenia patients
in CATIE, we documented a significant elevation in 10-year CHD risk compared to age, race
and gender-matched controls from the National Health and Nutrition Examination Survey
(NHANES). (Goff, Sullivan et al. 2005) Schizophrenia patients had higher rates of smoking,
diabetes, hypertension and lower HDL cholesterol levels.
Despite evidence that certain atypical antipsychotics predispose to weight gain, glucose and
lipid abnormalities, the effect of individual antipsychotics on overall CHD risk over time has
not been characterized previously. This is an important factor in evaluating risks versus benefits
of treatment and a crucial public health issue for patients with schizophrenia and others using
these medications. (American Diabetes Association and American Psychiatric Association,
2004) Phase 1 of the CATIE Schizophrenia Trial provides a unique opportunity to examine
this critical question. Thus, the study objective was to assess the effect of specific
antipsychotics on estimates of 10-year coronary heart disease risk in patients with
schizophrenia. We hypothesized there would be a differential CHD risk associated with the
various drugs used in CATIE participants and that changes in total and HDL cholesterol,
hypertension and diabetes would vary by treatment.
2.0 Methods
2.1 Study setting and Design
The CATIE Schizophrenia Study was conducted between January 2001 and December 2004
at 57 U.S. sites and included an algorithmically determined series of treatment phases. (Stroup,
McEvoy et al. 2003) A total of 1460 patients were randomized to receive olanzapine,
perphenazine, quetiapine, or risperidone under double-blind conditions and followed for up to
18 months or until initial treatment discontinuation. Two hundred thirty-one patients with
tardive dyskinesia (TD) were excluded from assignment to perphenazine; ziprasidone was
added to the study in 2002. Randomization thus took place under four strata within which
patients had an equal chance of being randomly assigned to treatments: TD patients pre-
ziprasidone (randomized to olanzapine, quetiapine, or risperidone), non-TD patients pre-
ziprasidone (randomized to olanzapine, quetiapine, risperidone or perphenazine), and these
two groups in the cohort of patients after ziprasidone was added. Patients whose assigned
treatment was discontinued could receive other treatments in phases 2 and 3. This analysis
reports on phase 1 results.
2.2 Study population
An IRB at each site approved the study. Participants were outpatients with schizophrenia
diagnosed by a research psychiatrist using a modified SCID interview and were between 18
and 65 years old. After complete description of the study to the subjects, written informed
consent was obtained. The analysis population consists of 1460 patients randomized in the
CATIE study. Of these, 10-year CHD risk was calculable at baseline and end of phase 1 for
1125 patients. We also performed an analysis restricted to subjects with fasting blood samples
at baseline and three months for a more sensitive and uniform risk factor assessment. This
analysis was limited to 283 subjects, of whom change in 10-year CHD risk was calculable for
270. Results were generally consistent with study population results, although harder to
interpret due to small sample sizes. They are included in the Appendix.
2.3 Measures
During comprehensive medical evaluations patients were asked about current medications,
cigarette smoking and whether they had been diagnosed or treated for hypertension or diabetes.
Vital signs, weight and smoking status were collected at screening, months 1, 3, 6, 9, 12, 15,
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18 and end of phase 1 (up to 18 months). Patients were instructed to fast overnight to measure
serum glucose, total cholesterol and HDL cholesterol. Laboratory measures were collected at
baseline, month 3, 6, 12, 18, and end of phase and were considered fasting if ≥8 hours after
ingesting food or calorie containing beverages.
2.4 Primary outcome
The primary outcome was change in 10 year CHD risk using the Framingham Heart Study
formula by Wilson, et.al. (Wilson, D'Agostino et al. 1998) Inputs to this formula include age,
total and HDL cholesterol (mg/dL), blood pressure stage (Fifth Joint National Committee
(JNC-V)) (Joint National Committee on Detection, Evaluation and Treatment of High Blood
Pressure, 1993), presence of diabetes mellitus and presence of smoking. Separate prediction
models are used for men and women. The formula reports the average risk (percent) of
developing CHD over a 10-year period. Changes in CHD risk are reported here as absolute
changes in risk estimates between end of phase and baseline. For example, if a person with
baseline risk of 9.0% had an increase of 0.8%, this corresponds to a new CHD risk of 9.8%.
All calculations use baseline age so changes in CHD risk reflect risk factors other than aging.
2.5 Secondary outcomes
Secondary outcomes were changes in diabetes, smoking status, hypertension, total cholesterol
and HDL by antipsychotic treatment. We classified participants as having diabetes mellitus at
baseline if they had a fasting glucose of ≥126 mg/dl, random glucose of ≥200 mg/dl, current
use of oral hypoglycemics or insulin, or a medical history of diabetes. At follow-up, we
classified participants with diabetes if they met baseline criteria or any of the following during
follow-up: new oral hypoglycemic medications or insulin; fasting glucose of ≥126 mg/dL;
random glucose of ≥200mg/dl or new diagnosis of diabetes recorded.
Participants had hypertension at baseline if they had a systolic blood pressure of ≥140 mm Hg,
diastolic blood pressure of ≥90 mmHg or if they took an antihypertensive. At follow-up,
participants were considered to have hypertension if they met blood pressure criteria at the end
of phase visit or if they were taking antihypertensive medication either at baseline or during
follow-up.
Patients were considered to be smokers at baseline or follow-up if they reported smoking five
or more cigarettes daily over the previous week.
2.6 Statistical Analyses
Treatment groups were compared for baseline values of the Framingham risk score, items
contributing to its calculation, demographic characteristics, and phase 1 treatment duration
with 4 degree of freedom (df) analysis of variance (ANOVA) or chi-squared tests.
For the primary analysis, unadjusted treatment means of the change from baseline in 10-year
CHD risk at end of phase and at 3 months were compared using an ANOVA. If the overall 4
df test was significant at p < 0.05, then the 10 treatment pairwise comparisons were made using
Bonferroni correction to maintain the overall Type I error rate at 0.05, yielding an alpha of
0.05 / 10=0.005. Due to the relatively conservative nature of this correction, p-values between
0.005 and 0.01 are also identified for the reader’s discretion. Treatment comparisons were then
refined by analysis of covariance (ANCOVA) adjusting for baseline risk and phase 1 treatment
duration, as well as demographic and other baseline measures found to be associated with
change in CHD risk. CATIE study design factors for study entrance after ziprasidone treatment
option was added, and for having TD at baseline were also evaluated for inclusion. Fasting
status at baseline and end of phase 1 was also considered as a possible covariate. Age and
gender were not covariates since they are used within the risk score calculation. Interactions
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between treatment group and significant covariates were explored, and for identified
interactions, treatment groups were compared within levels of the covariate using additional
ANCOVA models.
Treatment groups were compared for change from baseline in the secondary categorical
outcomes of smoking status, diabetes, and hypertension by a mean-score chi-square test for
ordinal data (4 df). Change from baseline in the secondary continuous outcome measures of
HDL and total cholesterol was evaluated similar to the primary outcome. Age and gender were
also considered as potential covariates in these ANCOVA models. The end of phase analyses
of these outcomes were based on the subset of the 1460 randomized patients for whom those
data were available for at least one follow-up visit. Similarly at 3 months, secondary outcomes
were analyzed for the subset of the 283 patients fasting at baseline and 3 months with data
available. In addition, change from baseline in the total and HDL cholesterol measurements
collected at 3, 6, 12 and 18 months were compared across treatment groups with a mixed model
including terms representing the baseline value of the dependent variable, time (treated as a
classification variable), other covariates determined to be important in adjusted analyses, and
terms representing baseline–by-time and treatment–by-time interactions. A random subject
effect and a spatial power covariance structure were used to adjust standard errors for
correlation of observations within-individual.
3.0 Results
3.1 Baseline participant characteristics
Table 1 depicts baseline demographics, cardiovascular risk factors and phase 1 treatment
duration overall and by gender for the 1125 primary analysis participants, 839 males and 286
females, for whom change in 10-year CHD risk was available. The mean age was 40.7 (SD
11.1) years, and the sample was 75 percent male and 62 percent white. Twelve percent of the
population had diabetes mellitus, 58 percent smoked cigarettes, and 34 percent had
hypertension. Females’ mean 10 year CHD risk was significantly lower than males, at 5.7
percent compared to 9.5 percent. Females’ lower prevalence of cigarette smoking (50 vs. 61
percent) and higher HDL (47.1 vs. 42.0 mg/dl) contributed to this lower CHD risk. Although
females had higher mean BMI (32.8 vs. 29.0 kg/m2) than males, BMI is not included in the
Framingham formula.
The baseline estimated 10 year CHD risk ranged from 8.1 to 9.1% across antipsychotic
medications. Demographic characteristics, cardiac risk factors and estimates of 10 year cardiac
risk were similar across treatment groups. Average phase 1 treatment duration was 9.5 months,
ranging from 8.2 to 11.3 months across the groups (p<0.001). The Appendix Table 1 shows
corresponding baseline measures for 270 participants with fasting serum values at baseline and
3 months for whom change in 10-year CHD risk was available.
3.2 Change in 10-year coronary heart disease risk estimates
The covariate-adjusted change in 10 year coronary heart disease risk estimate significantly
differed between treatment groups (p=0.007) (Table 2). The risk estimates were highest for
olanzapine then quetiapine and lowest for risperidone and ziprasidone followed by
perphenazine. Individual comparisons between treatment groups revealed a significant
difference between risperidone (−0.6, SE= 0.3) and olanzapine (0.5, SE= 0.3) (p=0.004). The
Appendix Table 2 shows CHD risk results for participants with fasting serum values at baseline
and 3 months. Although the sample sizes were substantially smaller, the adjusted 3-month
change from baseline in 10-year risk was very similar to those at end of phase for olanzapine,
quetiapine and risperidone. However, the 3-month analysis showed greater decrease for the
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perpenazine group compared to endpoint, and a deterioration rather than an improvement for
ziprasidone.
3.3 Change in 10-year coronary heart disease risk estimates by baseline risk, age and gender
We identified an interaction between antipsychotic treatment assignment and CHD risk status
at baseline, and report change in CHD risk for three baseline risk categories which approximate
the tertiles (Figure 1). The covariate-adjusted change in 10-year cardiac risk was significantly
different across the five treatment arms for participants with a baseline CHD risk of 10% or
greater (p=0.017). In this subgroup, the risk for risperidone-treated patients (−3.2, SE= 0.6)
remained lower than that for olanzapine (−0.9, SE= 0.6), although not statistically significant
with Bonferroni correction (p=0.008). For participants with less than 10% baseline CHD risk,
change in risk did not differ across treatment groups.
Treatment comparisons for change in CHD risk were also examined by age and gender (Table
2). For those under 40 years of age, the change in CHD risk was significantly different across
the antipsychotic groups (p=0.016) with olanzapine associated with increased risk compared
to perphenazine (p=0.004) and ziprasidone (p=0.004) (Table 2). In participants ages 50 years
and older, the change in CHD risk also significantly differed across the 5 antipsychotic groups
(p=0.008), with olanzapine associated with significantly greater increase in risk compared to
risperidone (p=0.002). The change in risk for quetiapine was also numerically higher than for
risperidone (p=0.009), but not statistically significant with Bonferroni correction. The change
in risk did not differ across the five treatment arms for the 40–49 age group. In addition, the
overall change in 10 year estimated CHD risk differed significantly in male (p=0.017) but not
in female subjects. In men, olanzapine was associated with numerically higher CHD risk
compared to perphenazine (p=0.007) and risperidone (p=0.008), although not statistically
significant with Bonferroni correction. Change in CHD risk at 3 months is also reported by
age, gender, and baseline risk categories in the Appendix Table 2, although treatment
comparisons were not made due to very small samples sizes in these subgroups.
3.4 Changes in individual coronary heart disease risk factors
Analysis of individual cardiac risk factors revealed no difference between treatment groups
for change in smoking status, new-onset diabetes or hypertension during phase 1. (Table 3).
However, a trend for reduction in hypertension at 3 months was noted in the perphenazine
group (Appendix Table 3). Changes in total and HDL cholesterol at end of phase significantly
differed between groups (p<0.001 and p=0.002, respectively, adjusted comparisons) (Table 4).
Total cholesterol was lowered more with risperidone (−11.2 mg/dl, SE=2.0) compared to
olanzapine (0.8 mg/dl, SE=2.0, p<0.001) and quetiapine (−2.2 mg/dl, SE=2.0, p=0.002),
whereas total cholesterol with ziprasidone (−9.3, SE=2.8) was lowered more than olanzapine
only (p=0.003) (Figure 3). A similar result was noted between risperidone and quetiapine in
the 3-month fasting cohort (Appendix Table 4).
Across all patients, covariate-adjusted HDL cholesterol levels decreased in olanzapine (−1.4,
mg/dl SE=0.5) compared to an increase in perphenazine (1.1 mg/dl, SE=0.6, p=0.001) and
ziprasidone (1.9 mg/dl, SE=0.7, p<0.001). However, an interaction between treatment and race
was identified. For whites, HDL was significantly increased in the perphenazine treatment
group (2.7 mg/dl, SE= 0.7) compared to olanzapine (−1.7 mg/dl, SE=0.6; p<0.001) and
quetiapine (−0.2 mg/dl, SE= 0.6; p=0.002) (Figure 3). For non-whites, ziprasidone-treated
patients had an increase in HDL (4.3 mg/dl, SE= 1.4) compared to a decrease for both
olanzapine (−0.9 mg/dl, SE=0.9; p=0.002) and perphenazine (−1.3 mg/dl, SE=1.0; p=0.001.)
(Figure 4). There was no difference between treatment groups for change in HDL at 3 months
(Appendix Table 4). Results of mixed model analyses for total and HDL cholesterol were
consistent with findings from the end of phase ANCOVA analyses (Figure 2–Figure 4).
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This prospective, randomized study provides an opportunity to study change in overall
coronary heart disease risk across antipsychotic treatments for patients with schizophrenia in
a large clinical trial. At baseline, study participants had high estimated 10-year CHD risk
compared to matched controls from the general population and had been treated for
schizophrenia for an average of 14 years. (Goff, Sullivan et al. 2005) In the relatively short
study time frame consisting of a maximum treatment exposure of 18 and mean of 9.5 (SD 7.0)
months, overall differences in estimated 10-year CHD risk between antipsychotics were
significant. Olanzapine and quetiapine were associated with increased risk; whereas risk
decreased in patients treated with perphenazine, risperidone, and ziprasidone. The difference
in 10-year CHD risk between olanzpaine and risperidone was statistically significant
(p=0.004). Differences between medication effects on risk were seen particularly in patients
with at least 10% baseline CHD risk, in subjects younger than 40 and older than 49, and in
men. Coronary heart disease risk increased, on average, for subjects with baseline risk
estimated at less than 10%, whereas average estimated risk was reduced in subjects entering
the study with estimated 10-year CHD risk of 10% or greater. Overall differences in CHD risk
between treatments appeared to result largely from lowering of total cholesterol in subjects
treated with risperidone and ziprasidone, and elevation of HDL cholesterol among Whites
treated with perphenazine and non-whites treated with ziprasidone.
While other work documents changes in individual CHD risk factors such as diabetes mellitus
and cholesterol from particular antipsychotics (Allison, Fontaine et al. 1999; 2004; Meyer and
Koro 2004; Newcomer and Haupt 2006), this analysis is distinctive in examining overall CHD
risk across several antipsychotics in the setting of a large, randomized clinical trial. Our results
also are consistent with those from a recent post-hoc analysis using the Framingham equation
to compare change in CHD risk in patients treated with olanzapine and ziprasidone in a 6 week
randomized clinical trial. (Del Valle, Loebel et al. 2006)
Differences in individual antipsychotic drug effects on CHD risk in the CATIE study appear
to be due principally to changes in total and HDL cholesterol. Whereas other agents tended to
decrease total cholesterol, olanzapine was associated with relative increases. Prior reports have
demonstrated large increases in triglyceride levels with olanzapine (Meyer 2002; Wirshing,
Boyd et al. 2002; Atmaca, Kuloglu et al. 2003), whereas risperidone and ziprasidone have been
associated with small or neutral effects on triglycerides and total cholesterol. (Kingsbury,
Fayek et al. 2001; Meyer 2002; Atmaca, Kuloglu et al. 2003; Weiden, Daniel et al. 2003) While
risperidone’s effects on weight gain and glucose elevation are similar to quetiapine,
(Lieberman, Stroup et al. 2005) because risperidone was associated with decreases in total
cholesterol in this study, its estimated CHD risk is comparable to that of ziprasidone and
perphenazine.
Quetiapine, which also increased mean 10-year CHD risk in those ages 50 years and older, has
been shown to increase trigylcerides, although most studies show a smaller impact on total
cholesterol levels compared to olanzapine. (Meyer 2001; Shaw, Lewis et al. 2001; Atmaca,
Kuloglu et al. 2003) Perphenazine decreased mean 10-year CHD risk compared to olanzapine
in those under 40 years, those 50 years and older and men, although previous studies have
shown that phenothiazines increase levels of trigylcerides and LDL. (Serafetinides, Collins et
al. 1972; Sasaki, Funakoshi et al. 1985)
Consistent with our hypothesis, effects on HDL cholesterol differed significantly among
antipsychotics, with only olanzapine associated with a consistent mean decrease (or worsening)
in HDL levels. To our knowledge, the mediating effect of race observed on perphenazine-
associated changes in HDL cholesterol has not been previously reported. Whites treated with
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perphenazine exhibited a mean increase in HDL cholesterol, whereas levels decreased in other
races. If replicated, identification of physiologic or molecular mechanisms underlying race
differences in antipsychotic effects on HDL will be of considerable interest.
The mechanisms for antipsychotic-related dyslipidemia are not fully understood. Certainly
weight gain and glucose intolerance are well known to increase risk of hyperlipidemia, yet we
also know that these factors are not necessary for antipsychotic-induced adverse changes in
lipid profiles to occur. (Meyer, Koro et al. 2005)
While we found significant differences in lipids across antipsychotic medications, we did not
see changes in the dichotomous risk factors of diabetes between drugs over the study. In part,
this may be due to our definition and the study’s limited duration. A patient could only obtain
a new diagnosis of diabetes but could not revert from diabetic to non-diabetic if blood sugars
decreased. In addition, any changes in glucose not meeting the threshold for diabetes did not
influence the calculation of CHD risk using the Framingham score. While the definition of
diabetes used for this analysis differs from that used in the original Framingham Study (i.e.,
two casual blood glucoses of 150 mg/dl or fasting of >140), it reflects the investigators’ best
attempt to categorize risk factors according to currently accepted definitions using available
study data.
We also did not see changes in hypertension status across antipsychotics. However, while the
hypertension definition we used also was dichomotous and does not reflect smaller, potentially
significant changes in blood pressure, hypertension in the Framingham score is more sensitive
and incorporates changes in JNC-V blood pressure stages (e.g., change from systolic 140–159
mmHg to 160 mmHg) We found qualitative differences in changing blood pressure stage by
antipsychotic, with approximately 36% of patients taking olanzapine, quetiapine or ziprasidone
worsening their blood pressure stage, and 27% of patients taking perphenazine or risperidone
worsening blood pressure stage. Fourteen percent of participants took anti-hypertensives at
baseline, and three percent initiated anti-hypertensives during the study; these did not differ
significantly by antipsychotic assignment. Meyer et.al. provides a more detailed analysis of
blood pressure and other components of the metabolic syndrome. (Meyer, Davis et al. in
press) We also clarify that the blood pressure criteria for the baseline CHD-risk CATIE sample
used systolic of >140 mmHg and diastolic >90 mmHg. (Goff, Sullivan et al. 2005) Blood
pressure criteria for the metabolic syndrome are systolic >=135 and diastolic >=85 mmHg.
(McEvoy, Meyer et al. 2005)
We found particular benefit in CHD risk reduction in those patients with greater than 10%
CHD risk at baseline treated with perphenazine, risperidone and ziprasidone. Using these
medications could have positive consequences in patients who already have clinical risk for
coronary disease including possible metabolic side effects from prior antipsychotics. While
there was no difference across treatment groups in patients with less than 10% baseline CHD
risk, it is notable that risk appeared to increase from baseline in almost all treatment groups.
To explore if switching or staying on an antipsychotic influenced CHD risk, we examined the
subsample of patients (n=216) who were on either olanzapine or risperidone prior to
randomization and were randomized to either of these two treatments. We found no statistically
significant difference in CHD risk between remaining or switching to the other antipsychotic
in this limited sample (results not shown).
In addition to results presented here, the Appendix includes results from the subpopulation of
participants with fasting laboratory samples at baseline and 3 months in order to approximate
our original baseline CHD risk analysis. (Goff, Sullivan et al. 2005) Numerically, findings
were similar overall, although the sample size for each treatment was very small.
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This study has limitations. First, although the CATIE Schizophrenia Trial is unique in its large
sample size and its examination of several antipsychotic therapies, CATIE was not designed
to examine CHD risk as a primary outcome. We attempted to match the Framingham definitions
of CHD risk factors, but definitions for hypertension, tobacco smoking and diabetes did differ
somewhat. Second, while the Framingham formula is valid across many populations, the
equation has not been validated in populations taking antipsychotics. The rapid and large
weight change associated with some antipsychotics substantially differs from typical weight
change patterns in the general population from which the risk equation was derived. Because
weight is not a variable in the Framingham equation, it is possible that the long-term impact
on cardiac health of rapid antipsychotic-induced weight gain may not be sufficiently captured.
Moreover, although triglycerides are part of total cholesterol which is in the Framingham
equation, the model does not specifically incorporate risk for triglycerides, which are increasing
in acceptance as an independent risk factor for coronary disease (Nordestgaard, Benn et al.
2007) and often the lipid fraction most affected by antipsychotics. We would expect inclusion
of weight and triglycerides in a CHD risk model would influence and likely enhance the
differences we found between antipsychotics with the Framingham model.
In conclusion, we found different antipsychotic treatments did indeed confer varying levels of
CHD risk in the CATIE Schizophrenia Trial. Subjects were treated with psychotropics 14 years
on average before joining the study, and much cardiovascular risk may have been expected to
have accumulated prior to the trial; this is supported by the high baseline Framingham risk
scores. Despite this high initial risk factor burden, CHD risk changes differed significantly in
magnitude across antipsychotic agents after only a few months of exposure. The absolute
magnitude of changes in CHD risk found with antipsychotic medications are comparable to
those seen in an intensive lifestyle modification program for adults with cardiac risk factors
and thus should be clinically important. (Ellsworth, O'Dowd et al. 2004) Olanzapine conferred
the highest risk of the antipsychotics, with quetiapine appearing to have similar risk.
Risperidone, ziprasidone and perphenazine were associated with lower overall risk. The largest
treatment differences in 10-year CHD risk were seen in participants with at least 10% baseline
CHD risk and in older subjects. When initiating or changing antipsychotic therapy, clinicians
should consider these changes in likelihood of coronary heart disease, particularly for older
patients and those with baseline coronary risk factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Change in 10 year Coronary Heart Disease (CHD) Risk by Baseline CHD Risk Categories
ANCOVA least squares adjusted results with Mean +/− SE. Model includes baseline risk, time
to treatment discontinuation, and fasting status at baseline and end of phase 1.
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Figure 2. Repeated Measures Estimates of Total Cholesterol Changes
Olanzapine shown in red; perphenazine shown in blue; quetiapine shown in green; risperidone
shown in yellow; ziprasidone shown in black dashed line.
Between group differences significant for olanzapine vs. risperidone (p<.001), olanzapine vs.
ziprasidone (p<.001) and quetiapine vs. risperidone (p=.001). Change numerically different
for olanzapine vs. perphenazine, but not statistically significant with Bonferroni correction
(p=.009).
Sample sizes by visit and treatment group are:
visit olanzapine perphenazine quetiapine risperidone ziprasidone
3 269 208 257 261 140
6 200 130 163 175 74
12 157 85 109 126 55
18 129 66 64 97 37
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Figure 3. Repeated Measures Estimates of HDL Cholesterol Changes for Whites
Olanzapine shown in red; perphenazine shown in blue; quetiapine shown in green; risperidone
shown in yellow; ziprasidone shown in black dashed line.
Between group differences significant in whites for perphenazine vs. olanzapine (p<.001),
quetiapine (p=.002), and risperidone (p=.003).
Sample sizes by visit and treatment group are:
visit olanzapine perphenazine quetiapine risperidone ziprasidone
3 161 122 179 157 89
6 117 82 108 108 43
12 96 49 72 79 35
18 79 41 45 63 24
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Figure 4. Repeated Measures Estimates of HDL Cholesterol Changes for Other Races
Olanzapine shown in red; perphenazine shown in blue; quetiapine shown in green; risperidone
shown in yellow; ziprasidone shown in black dashed line.
Between group differences significant in other races for ziprasidone vs. olanzapine (p<.001)
and perphenazine (p=.002).
Sample sizes by visit and treatment group are:
visit olanzapine perphenazine quetiapine risperidone ziprasidone
3 108 86 78 104 49
6 83 48 55 67 30
12 61 36 37 47 20
18 50 25 19 34 13
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Table 1
Baseline demographics, coronary heart disease risk factors, and duration of phase 1 treatment for CATIE subjects
overall and by gendera,b
Overall (n=1125) Males (n=839) Females (n=286)
Agec 40.7 ± 11.1 40.1 ± 11.3 42.5 ± 10.2
Whitec,d 701 (62) 543 (65) 158 (55)
Hispanic 133 (12) 98 (12) 35 (12)
Years of Educationd 12.1 ± 2.2 12.2 ± 2.2 12.1 ± 2.5
Diabetes 139 (12) 100 (12) 39 (14)
Cigarette smokerc 657 (58) 515 (61) 142 (50)
Hypertension 377 (34) 294 (35) 83 (29)
BMI (kg/m2)c,d 29.9 ± 7.0 29.0 ± 6.5 32.8 ± 7.6
Total Cholesterol (mg/dl) 202.2 ± 47.5 201.2 ± 47.5 205.1 ± 47.4
High Density Chol. (mg/dl)c 43.3 ± 13.4 42.0 ± 13.1 47.1 ± 13.8
10 year estimated CHD riskc
  Mean 8.5 ± 7.4 9.5 ± 7.5 5.7 ± 6.3
  < 5% 444 (39) 272 ( 32) 172 (60)
  5 to < 10% 316 (28) 256 (31) 60 (21)
  ≥ 10% 365 (32) 311 (37) 54 (19)
Phase 1 Treatment Duration 9.5 ± 7.0 9.6 ± 7.1 9.1 ± 6.9
a
Table entries are n (%) or Mean ± SD.
b
Based on 1125 subjects for whom change in 10-year CHD risk could be calculated.
c
Significantly different between males and females (p<0.05).
d
Percentages are based on number of patients with data available. For Whites, N=285 for females. For years of education: males, N=835; females, N=
285. For BMI: males, N=832; females, N=283.
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